Ratings Oxford Biomedica plc

Equities

OXB

GB00BDFBVT43

Real-time Estimate Cboe Europe Other stock markets 10:56:43 2024-04-23 am EDT			5-day change	1st Jan Change
217.2 ^GBX	+2.24%		+10.07%	-2.34%

Apr. 18	Stifel Upgrades Oxford BioMedica to Buy from Hold, Lifts PT	MT
Apr. 18	HSBC likes Haleon, cuts Flutter to 'hold'	AN

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
OXFORD BIOMEDICA PLC	-2.34%	262M	B
VERTEX PHARMACEUTICALS INCORPORATED	-0.14%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+3.58%	96.73B	B+
ARGENX SE	+1.40%	21.31B	B
BIONTECH SE	-15.38%	21.21B	B+
GENMAB A/S	-6.50%	18.79B	A-
WUXI APPTEC CO., LTD.	-41.41%	16.37B	A-
BEIGENE, LTD.	-21.99%	13.68B	B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	13.44B	C+
SAREPTA THERAPEUTICS, INC.	+24.16%	10.98B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes